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Abstract
Background:  Retrodifferentiation and regained proliferative capacity of growth-arrested human
leukemic cells after monocyte-like differentiation requires proteolytic activities together with distinct
regulatory factors. The AAA ATPase valosin-containing protein (VCP/p97) contributes to protein
degradation and cell cycle regulation, respectively, and it was of interest to study a possible role of VCP/
p97 during this myelomonocytic differentiation and retrodifferentiation.
Results: Separation of autonomously proliferating human U937 myeloid leukemia cells by centrifugal
elutriation demonstrated unaltered VCP/p97 expression levels throughout distinct phases of the cell cycle.
However, phorbol ester-induced G0/G1 cell cycle arrest in differentiating human U937 leukemia cells was
associated with a significantly increased protein and mRNA amount of this AAA ATPase. These elevated
VCP/p97 levels progressively decreased again when growth-arrested U937 cells entered a
retrodifferentiation program and returned to the tumorigenic phenotype. Whereas VCP/p97 was
observed predominantly in the cytosol of U937 tumor and retrodifferentiated cells, a significant nuclear
accumulation appeared during differentiation and G0/G1 growth arrest. Analysis of subcellular
compartments by immunoprecipitations and 2D Western blots substantiated these findings and revealed
furthermore a tyrosine-specific phosphorylation of VCP/p97 in the cytosolic but not in the nuclear
fractions. These altered tyrosine phosphorylation levels, according to distinct subcellular distributions,
indicated a possible functional involvement of VCP/p97 in the leukemic differentiation process. Indeed, a
down-modulation of VCP/p97 protein by siRNA revealed a reduced expression of differentiation-
associated genes in subsequent DNA microarray analysis. Moreover, DNA-binding and proliferation-
associated genes, which are down-regulated during differentiation of the leukemic cells, demonstrated
elevated levels in the VCP/p97 siRNA transfectants.
Conclusion: The findings demonstrated that monocytic differentiation and G0/G1 growth arrest in human
U937 leukemia cells was accompanied by an increase in VCP/p97 expression and a distinct subcellular
distribution to be reverted during retrodifferentiation. Together with a down-modulation of VCP/p97 by
siRNA, these results suggested an association of this AAA ATPase in the differentiation/
retrodifferentiation program.
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Background
The human myeloid leukemia cell line U937 represents a
well-characterized in vitro tumor model of differentiation
and retrodifferentiation, which can be induced to differ-
entiate along the monocyte/macrophage-like pathway
after treatment with 12-O-tetradecanoyl-phorbol-13-ace-
tate (TPA) [1]. During this differentiation process, the
autonomously proliferating tumor cells become adherent,
undergo a complete growth arrest and acquire a variety of
morphological and functional changes typical for normal
monocytes and macrophages [1-5]. The TPA-differenti-
ated U937 cells remain and survive in a transient G0'
growth arrest cycle [6,7]. After 2–3 weeks in the absence of
TPA, however, the differentiated population down-modu-
lates all markers acquired during the previous differentia-
tion process and re-enters the proliferative cell cycle by a
retrodifferentiation program, which results in the undif-
ferentiated phenotype [6-8]. Recent studies on the mech-
anism of this retrodifferentiation process revealed the
necessity of a tightly regulated protein modulation pro-
gram, which involves the cellular proteasome [9] and a
variety of regulatory compounds, including the nuclear
factor poly(ADP-ribose)polymerase [10]. However, since
fundamental cellular functions are altered and reverted in
this differentiation and retrodifferentiation model [11],
the precise signaling pathways for the coordination of this
phenomenon remain unclear and may thus involve fur-
ther regulatory compounds of the proteasome, including
certain ATPases.
The valosin-containing protein (VCP), also termed p97,
belongs to the AAA superfamily (ATPases associated with
a variety of cellular activities) and represents the mamma-
lian homolog of Cdc48 in yeast [12]. VCP/p97 is one of
the most abundant proteins in cells and is ubiquitously
expressed in all eukaryotic cells. Thereby, it is involved in
multiple cellular effects and performs a large variety of dif-
ferent cellular functions, including transport mechanisms,
protein degradation and cell cycle regulation, respectively
[13]. In this context, previous work has demonstrated that
VCP/p97 targets numerous ubiquitinated substrates to the
proteasome for subsequent degradation and may thus act
as a general chaperone [14]. This concept is also reflected
during cell cycle regulation [15], whereby VCP/p97 is
associated with the degradation of decisive cell cycle regu-
latory proteins via the ubiquitin-proteasome pathway. For
example, the mammalian cyclin E, which is required for
the entry of cells into S phase [16], and the G1-CDK inhib-
itor Far1 are both affected in their stability by interference
with VCP/p97 and subsequent proteasomal degradation
[14,17]. However, the precise interaction of VCP/p97 and
different signal cascades are unknown so far. Moreover,
the activation process of VCP/p97 in distinct subcellular
compartments and possible modifications, e.g. by phos-
phorylation, remains obscure.
VCP/p97 has been demonstrated to localize predomi-
nantly in the cytosol. However, according to its involve-
ment in membrane fusion, this protein is also associated
with various membranes of organelles such as the Golgi
and the endoplasmic reticulum [18,19]. Nuclear localiza-
tion of VCP/p97 was determined by interactions with
Werner protein, a RecQ helicase [20], and during spindle
disassembly [21]. Phosphorylation of VCP/p97 on tyro-
sine residues is suggested to play a role in determining the
appropriate subcellular localization [15,22]. In addition,
after DNA damage, VCP/p97 is phosphorylated at Ser784
[23]. Interestingly, the phosphorylation does not affect
the VCP/p97 ATPase activity and therefore, the physiolog-
ical relevance of these modifications remains unknown
[24].
VCP/p97 has a variety of clinical implications and thus
contributes to the pathogenesis of distinct human dis-
eases. In this context, VCP/p97 plays a role in several neu-
rodegenerative disorders, which may be associated with
its chaperone-like function as a cell death effector mole-
cule [25-27]. Furthermore, VCP/p97 is discussed to be
involved in certain types of human tumors such as hepa-
tocellular and colorectal carcinomas as well as breast can-
cer [13,27,28]. In addition, VCP/p97 may increase the
metastatic potential in tumor entities, possibly by control-
ling the stability of IκBα, an inhibitor of NFκB [29,30]. Up
to now the role of VCP/p97 during a cancer development
is poorly understood. We therefore aim to characterize
this ATPase in an in vitro cancer model of differentiation
and retrodifferentiation to provide additional informa-
tion for a potential role and function during tumorigene-
sis.
The predominant focus of the present study was 1) to
examine the VCP/p97 expression in distinct cell cycle
phases of proliferating U937 cells; 2) to analyze the regu-
lation of VCP/p97 during differentiation-associated G0/
G1 cell cycle exit and subsequent retrodifferentiation of
U937 cells; 3) to investigate a possible functional associa-
tion of VCP/p97 with the differentiation process.
Results
Previous studies have demonstrated an essential role for
VCP/p97 in cell cycle regulation [14,17]. In order to inves-
tigate the expression of VCP/p97 during the cell cycle, cen-
trifugal elutriations of proliferating U937 cells were
performed to separate cells within distinct phases of the
cell cycle (Fig. 1). Western blot analysis of the elutriated
U937 cell lysates demonstrated little if any difference in
the 97 kDa protein VCP/p97 levels throughout the cell
cycle (Fig. 1A). Control of the elutriated cell cycle phases
and quantification of the distribution was performed by
flow cytometry (Fig. 1B, 1C). A tyrosine phosphorylation
of an approximately 97 kDa protein was present in the G1-BMC Cell Biology 2008, 9:12 http://www.biomedcentral.com/1471-2121/9/12
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enriched populations and remained undetectable in S
phase-enriched cells and during G2/M phase (Fig. 1). β-
actin, which served as a loading control, was similarly
expressed throughout the cell cycle (Fig. 1).
Next, we investigated VCP/p97 protein expression during
growth arrest and differentiation. Treatment of U937 cells
with 10 nM of the phorbol ester 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) for 72 h was associated with cell
cycle arrest in G0' and subsequent differentiation along
the monocytic/macrophage-like pathway [1,6]. Long term
culture of these growth-arrested and differentiated cells in
the absence of TPA for approximately 3 weeks was accom-
panied by a retrodifferentiation process, whereby the dif-
ferentiated cells down-modulate all previously acquired
differentiation markers and re-enter the proliferative cell
cycle [6,7]. Indeed, TPA-induced differentiation of U937
cells demonstrated a significant expression of the cell
cycle inhibitor p21Cip1/Waf1/sdi-1 [31] within 3 d, which was
down-regulated during retrodifferentiation (Fig. 2A).
Simultaneously, the differentiation-associated intermedi-
ate filament protein vimentin [3] also exhibited marked
expression during differentiation in contrast to a very low
detection level in U937 control and retrodifferentiated
VCP/p97 expression during cell cycle distribution of synchronized U937 cells Figure 1
VCP/p97 expression during cell cycle distribution of synchronized U937 cells. A. U937 cells were separated by cen-
trifugal elutriation and cell lysates of the appropriate fractions were analyzed by Western blot using an anti-VCP/p97 and an 
anti-phosphotyrosine antibody, respectively. Expression of β-actin was used as a loading control. B. The cell cycle distribution 
of the appropriate elutriated cell fractions were analyzed by flow cytometry and histograms were generated by the FloMax 
software. C. Quantification of the cell cycle distribution of the elutriated fractions and the percentage of the distinct cell cycle 
phases was gated and calculated using the MultiCycle software.
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Alteration of the VCP/p97 expression during differentiation and retrodifferentiation Figure 2
Alteration of the VCP/p97 expression during differentiation and retrodifferentiation. A. U937 cells were treated 
initially with 10 nM TPA and then cultured in the absence of TPA until retrodifferentiation. At the time points indicated, cell 
lysates were separated by 10% SDS-PAGE followed by Western blot analysis with anti-VCP/p97, anti-P-tyr, anti-p21Cip1/Waf1/sdi-
1 and anti-vimentin antibody. The tyrosine phosphorylation pattern (p-tyr) is demonstrated by the complete range from 250-20 
kDa. Staining with β-actin was used as a loading control. Densitometric analysis and normalization to β-actin was performed 
using the ImageJ software (NIH, Bethesda, MD, USA). B. Quantitative RT-PCR analysis of VCP/p97 mRNA levels during differ-
entiation and retrodifferentiation. Following total RNA isolation of undifferentiated U937 control cells (U937), differentiated 
populations (3d until 18d) and retrodifferentiated U937 cells (Retro), the amplification was performed in the LightCycler 2.0 
System using the LightCycler Software 3.5. Results represent means ± SD from three independent experiments.
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cells (Fig. 2A). Expression of VCP/p97 was significantly
elevated after 3 d of TPA exposure and this expression con-
tinuously decreased until the cells entered retrodifferenti-
ation to reach the same VCP/p97 protein levels observed
in untreated control cells (Fig. 2A). Similar findings were
observed for tyrosine-phorphorylated proteins at approx-
imately 97 kDa, demonstrating a marked presence after 3
d of TPA incubation and a progressive decline thereafter
(Fig. 2A). Western blots were normalized to the β-actin
levels by densitometry using the ImageJ software (NIH,
Bethesda, MD, USA).
Following quantitative RT-PCR analysis of VCP/p97, the
measurements were normalized to the uniformly tran-
scribed mRNA of the TATA-binding protein (TBP). In
agreement with the Western blot data, mRNA expression
of VCP/p97 was significantly enhanced after 72 h of TPA
induction and thereafter, the transcripts progressively
decreased until the level of retrodifferentiated cells was
indistinguishable to that observed in U937 control cells
(Fig. 2B). Together, these data indicated a possible associ-
ation of VCP/p97 with the differentiation process and the
transient cell cycle arrest.
Phase contrast pictures clearly showed the distinct mor-
phology of the differentiated U937 cells. Using staining
with the DNA-intercalating dye Hoechst 33258, the
appropriate compartments of the nuclei within these cells
could easily be demonstrated (Fig. 3). Subcellular locali-
zation of VCP/p97 during the differentiation process was
analyzed by immunofluorescence. Undifferentiated and
retrodifferentiated U937 cells revealed a predominant
localization of VCP/p97 in both, the cytoplasm and the
plasma membrane, whereas there was less evidence for
VCP/p97 localization in the nucleus of these cells (Fig.
3A). In contrast, the differentiated cell populations dem-
onstrated opposite effects: A localization of VCP/p97 in
the cytoplasm as well as a membrane association was par-
alleled by a pronounced immunofluorescence in the
nucleus of all differentiated populations (Fig. 3A). The
specificity of the VCP/p97 antibody was tested using an
appropriate neutralizing peptide (Fig 3B). These data sug-
gested that a significantly increased expression and an
enhanced nuclear localization of VCP/p97 accompany
differentiation and cell cycle arrest, which is reverted dur-
ing the retrodifferentiation program.
In order to validate these findings, distinct subcellular
compartments were separated and analyzed by Western
blotting (Fig. 4). Predominant expression of GAPDH in
the cytosol, clathrin in the membrane-associated fraction,
and nucleoporin62 in the nucleus, respectively, demon-
strated a successful enrichment of the appropriate subcel-
lular fractions (Fig. 4A). Western blot analysis revealed a
different expression of VCP/p97 in distinct cellular com-
partments during differentiation and retrodifferentiation
(Fig. 4B). Whereas little if any differences in the expres-
sion of VCP/p97 were detectable in the cytosol, VCP/p97
protein levels significantly increased in the membrane
fraction after TPA induction, most predominantly at day
3, and returned back to control levels during the retrodif-
ferentiation program (Fig 4B). Moreover, VCP/p97
expression in the nucleus was significantly elevated after
TPA exposure most predominantly at day 11, and simi-
larly returned to control levels at the time of retrodifferen-
tiation (Fig. 4B). Whereby total amounts of VCP/p97 in
the subcellular compartments were not quantified, an
apparent inconsistency by comparison of these subcellu-
lar VCP distributions to the pattern observed in the time
course of the total cell lysates (Fig. 2) may results from an
unequal distribution, suggesting most of the VCP/p97
within the cytosol and membrane-associated as compared
to the nuclear fraction.
Investigations of tyrosine phosphorylations within these
subcellular compartments demonstrated a phosphoryla-
tion pattern of an approximately 97 kDa protein in the
cytosol and the membranes similar to that observed for
VCP/p97 in these compartments (Fig. 4B). In contrast,
there was little if any tyrosine phosphorylation detectable
at 97 kDa in the nucleus during differentiation and retro-
differentiation (Fig. 4B). Analysis of the Coomassie stain-
ing in the cytosol, membrane fraction and the nuclear
compartment, respectively, served as an appropriate load-
ing control. The protein levels were normalized to the
Coomassie staining by densitometric analysis (Fig. 4B).
These data suggested a distinct subcellular distribution of
VCP/p97 during the differentiation process and cell cycle
arrest associated with tyrosine phosphorylation exclu-
sively in the cytosol and membranes.
For characterization of these findings, we performed an
anti-phosphotyrosine immunoprecipitation of the sub-
cellular fractions in undifferentiated U937 and differenti-
ated cells, exemplarily shown 11 days after TPA induction
(Fig. 5A). VCP/p97 Western blot analysis of the phospho-
tyrosine-precipitated proteins revealed a distinct band in
the molecular range of approximately 97 kDa in the
cytosolic as well as in the membrane fractions of both,
undifferentiated and differentiated cells. In contrast, little
if any VCP/p97 was detectable in the nuclear fraction of
either U937 control or differentiated cells (Fig. 5A). These
data were supported by anti-VCP/p97 cross-immunopre-
cipitations followed by phosphotyrosine Western blots
with a signal at approximately 97 kDa in the cytosolic and
membraneous fractions of U937 and differentiated cells
but no detectable phosphorylation in either nuclear frac-
tion (Fig. 5A). Analysis of the protein amount in each frac-BMC Cell Biology 2008, 9:12 http://www.biomedcentral.com/1471-2121/9/12
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Subcellular localization of VCP/p97 in undifferentiated controls (U937), differentiated populations (3d, 7d, 14d) and retrodiffer- entiated U937 cells (Retro) by immunofluorescence Figure 3
Subcellular localization of VCP/p97 in undifferentiated controls (U937), differentiated populations (3d, 7d, 
14d) and retrodifferentiated U937 cells (Retro) by immunofluorescence. A. VCP/p97 was visualized by a secondary 
FITC-conjugated rabbit anti-goat antibody (VCP-Ab). The nuclei were stained with the DNA-intercalating dye Hoechst 33258. 
B. The VCP/p97 antibody was neutralized with a specific blocking peptide and incubated with a secondary FITC-conjugated 
rabbit anti-goat antibody (VCP-Ab + VCP-peptide). The nuclei were stained with the DNA-intercalating dye Hoechst 33258.
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Subcellular regulation of VCP/p97 during differentiation and retrodifferentiation Figure 4
Subcellular regulation of VCP/p97 during differentiation and retrodifferentiation. A. The successful separation of 
the different U937 cell populations into subcellular compartments was controlled by GAPDH for the cytosol, clathrin for the 
membrane-fraction and nucleoporin62 (nup62) for the nucleus, respectively. B. Cytosol, membranes and nuclei of undifferenti-
ated U937 control cells (U937), differentiated populations (3d until 18d) and retrodifferentiated U937 cells (Retro), respec-
tively, were separated by SDS-PAGE, and VCP/p97 expression levels as well as the tyrosine phosphorylation patterns were 
examined by Western blot analysis. The Coomassie stain of the different fractions was used as a loading control. Densitomet-
ric analysis and normalization to the appropriate Coomassie stain was performed using the ImageJ software (NIH, Bethesda, 
MD, USA).
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tion was performed by anti-VCP/p97 immunoprecitation
and subsequent anti-VCP/p97 Western blot (Fig. 5A).
To further substantiate these findings, proteins of the
cytosolic and nuclear compartments from undifferenti-
ated and TPA-differentiated U937 cells were separated by
non-linear isoelectric focusing (NL-IEF) and subsequent
SDS-PAGE in the second dimension, respectively, fol-
lowed by anti-VCP/p97 and anti-phosphotyrosine immu-
noblotting, respectively (Fig. 5B). The cytosolic 2D VCP/
p97 Western blot of U937 and TPA-differentiated U937
cells demonstrated a distinct spot in the molecular range
of 97 kDa and an isoelectric point of approximately pH
5.1 respectively (Fig. 5B). Stripping and rehybridization of
these 2D blots with the anti-phosphotyrosine antibody
revealed the same phosphorylated spots at about 97 kDa,
pH 5.1, among a variety of other phosphorylated proteins
(Fig. 5B). In the nuclear fraction of U937 cells, the 2D
VCP/p97 Western blot could not visualize any protein
spot and accordingly, no phosphorylation was detectable
at about 97 kDa, pH 5.1 (Fig. 5B). In contrast, the nuclear
fraction of TPA-differentiated U937 cells demonstrated a
Subcellular tyrosine-phosphorylation pattern of VCP/p97 Figure 5
Subcellular tyrosine-phosphorylation pattern of VCP/p97. A. Immunoprecipitation of subcellular compartments during 
U937 differentiation and subsequent Western blot analysis. Cytosol, membranes, and nuclei of undifferentiated U937 control 
cells (U937) and 11d differentiated populations (TPA-differentiated U937), respectively, were immunoprecipitated with an anti-
phosphotyrosine antibody (IP: P-tyr) followed by an anti-VCP/p97 Western blot (WB: VCP). A cross-immunoprecipitation was 
performed with anti-VCP/p97 (IP: VCP) and subsequent anti-phosphotyrosine Western blot (WB: P-tyr). Protein controls 
were evaluated by anti-VCP/p97 immunoprecipitation (IP: VCP) followed by anti-VCP/p97 Western blot (WB: VCP). B. 2D-
Western blot analysis of cytosolic and nuclear fractions during U937 differentiation. Cytosolic and nuclear proteins from U937 
control cells (U937) and 7d TPA-differentiated cells were separated by non-linear isoelectric focusing (pH 3–10, NL) and sub-
sequent 10% SDS-PAGE in the second dimension. Western blot analysis was performed with an anti-VCP/p97 antibody (VCP) 
and after successful stripping, which revealed no detectable spots anymore (data not shown), the same blots were incubated 
with an anti-phosphotyrosine antibody (P-tyr) and developed by the ECL kit.
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clear VCP/p97 protein spot at approximately 97 kDa, pH
5.1 and subsequent anti-phosphotyrosine Western blot
did not reveal any phosphorylation of this protein spot
(Fig. 5B), which is in line with our previous data. Control
exposure of the stripped blots and control hybridizations
with the secondary antibody alone revealed no detectable
signals, respectively (data not shown).
A possible functional role of VCP/p97 in differentiating
U937 cells was addressed by a siRNA approach. The trans-
fection method was tested with a FITC-conjugated control
siRNA which revealed a transfection efficiency in U937
cells of >95% as evaluated by FACS analysis (Fig. 6A). The
successful down-modulation of VCP/p97 protein in VCP-
siRNA-transfected cells was demonstrated in appropriate
Western blots for both, U937 control and TPA-differenti-
ating cells (Fig. 6B). Functional changes in VCP-siRNA-
transfected cells following phorbol ester-induced mono-
cytic differentiation have been examind by DNA microar-
ray analysis (Fig. 6C, D). Thus, differentiation-associated
genes, which are elevated during myelomonocytic matu-
ration, including the cytokine receptor for interleukin-1,
were expressed at significantly reduced levels in TPA-
treated VCP/p97-siRNA-transfected U937 cells. According
to the cell attachment as a consequence of differentiation
along the monocytic/macrophage-like pathway, genes
associated with the formation of the cytoskeleton (e.g.
adducin1) and certain extracellular matrix related genes
such as ADAM metalloproteinase 13 and the extracellular
glycoprotein fibronectin showed a decreased expression
due to VCP/p97 RNAi (Fig. 6C). Moreover, previous work
has demonstrated that TPA-mediated signals in U937 cells
are relayed via activation of protein kinase C and down-
stream kinases to activate appropriate transcription fac-
tors for the induction of differentiation-associated genes
[8]. In this context, pleckstrin homology domain contain-
ing proteins, a MAP kinase interacting protein and phos-
pholipase C were significantly down-modulated in TPA-
treated VCP-siRNA-transfectants (Fig. 6C). With respect to
genes involved in protein metabolism and particularly in
transport functions, sulfotransferase 2A, an ATPase
(ATP8B3), a vesicle transport protein (SFT2D3) and a
Golgi-associated gene (COG1) were reduced expressed
(Fig. 6C). In contrast, the KDEL receptor was up-regulated,
which is responsible for the retention of newly synthe-
sized proteins during the quality control in the ER [32]
(Fig 6D). Moreover, metabolic compounds involved in
post-translational modifications in the lysosome and
microsome such as β-glucoronidase, arylacetamide
deacetylase, phosphoserine aminotransferase and xylo-
sysltransferase were increased expressed (Fig. 6D). TPA-
induced differentiation is also associated with growth
arrest and down-modulation of cell cycle-regulatory fac-
tors [9,10]. In contrast, TPA treatment of VCP-siRNA-
transfected U937 cells revealed an increased expression of
the transcriptional regulator ETV6 and certain histones.
(Fig. 6D). However, siRNA-targeting in cells also involves
off-target effects, which reflect VCP/p97-siRNA-independ-
ent modulations and some of these genes are listed in Fig-
ure 7.
In summary, the siRNA-targeted down-modulation of
VCP/p97 in differentiation-induced U937 cells revealed a
reduction of differentiation-associated genes and elevated
levels of DNA-binding and proliferation-related factors.
Discussion
Although the AAA ATPase VCP/p97 is involved in a variety
of pathophysiological processes, providing a potential
therapeutic target, the knowledge about its signaling cas-
cades remain scarce. Previous studies suggested an unal-
tered expression of VCP/p97 throughout the cell cycle
[14,17]. The results of the present study are in agreement
with these findings. Moreover, an enhanced VCP/p97
phosphorylation of the yeast homolog Cdc48 was
observed during spindle disassembly [15]. Cdc48 muta-
tions revealed the requirement of this ATPase for the
nuclear division process [19]. However, the role of VCP/
p97-associated phosphorylation patterns for regulatory
processes within the cell cycle remains unknown.
Cell cycle arrest in G0/G1 by TPA induction was associated
with a pronounced VCP/p97 accumulation both, in the
membranes and in the nucleus, which might be related to
enhanced protein turnover according to the functional
restructure of U937 cells during the concomitant differen-
tiation program. Supportive findings from recent work
indicated an involvement of VCP/p97 in transcriptional
regulation [13] as well as in proteasomal degradation dur-
ing differentiation. This effect was accompanied by a
membrane-association of VCP/p97 required for retro-
translocation of misfolded and unwanted proteins to the
cytosol with subsequent degradation by the ubiquitin-
proteasome system [33]. Although previous work has sug-
gested that elevated VCP/p97 expression is associated
with increased metastatic potential and tumor recurrence
in a variety of cancers, including hepatocellular, colorectal
and osteosarcomal carcinoma [27-30], the present find-
ings demonstrate an up-regulation of VCP/p97 during dif-
ferentiation and growth arrest. This differentiation
process is accompanied by the development of secretory
active cells requiring significant endoplasmic reticulum-
associated protein degradation [34,35] and thus VCP/p97
[36-38]. Previous data revealed that a down-modulation
of VCP/p97 results in a significant accumulation of ubiq-
uitinated and thus degradation-designated proteins,
which eventually promotes apoptosis [39]. This is sub-
stantiated by microarray studies in HeLa cells transfected
with VCP-siRNA, demonstrating a significant up-regula-
tion of transcripts encoding for proteins associated withBMC Cell Biology 2008, 9:12 http://www.biomedcentral.com/1471-2121/9/12
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siRNA transfection of U937 cells Figure 6
siRNA transfection of U937 cells. A. U937 cells (control U937) and cells transfected with a FITC-conjugated Negative 
Control siRNA AF488 (FITC-siRNA-transfected U937) were analyzed by FACS and revealed more than 95% transfection effi-
ciency by this method. B. Western blot analysis of U937 control cells (U937), U937 cells transfected with a negative control 
siRNA (neg. siRNA) and U937 cells transfected with a VCP/p97 siRNA (VCP siRNA) were analyzed for VCP/p97 protein 
expression 72 h after the transfection and in the presence of 10 nM TPA for 24 h (+TPA), respectively. C, D. cDNA microar-
ray analysis of VCP/p97 siRNA-transfected U937 cells during TPA-induced differentiation. U937 cells transfected with either 
negative control siRNA or VCP/p97 siRNA in the presence or absence of 10 nM TPA for 24 h, respectively, were subjected to 
cDNA microarray analysis provided by the Stanford Functional Genomics Facility. U937 control transfectants were compared 
to VCP/p97 transfectants and simultaneously TPA-treated control-transfectants were compared to the appropriate TPA-
treated VCP/p97 siRNA transfectants to exclude the genes affected by the transfection itself. Thereafter, the regulated genes 
of untreated and TPA-treated populations were compared in order to evaluate those transcripts affected by VCP/p97 during 
the differentiation process. Potential off-target effects have been addressed by separate analysis of the two distinct VCP/p97 
siRNAs in U937 and TPA-treated U937 cells, respectively. A representative panel of resulting down-modulated (C) and up-reg-
ulated (D) VCP/p97-affected genes during differentiation are demonstrated.
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gene name description of down-regulated gene fold change
IL1R2 Interleukin 1 receptor, type II -2,4
CREB3L2 CAMP responsive element binding protein 3-like 2 -2,0
ADAM30 ADAM metallopeptidase domain 30 -1,8
FSD1 Fibronectin type III and SPRY domain containing 1 -1,6
PSD Pleckstrin homology domain containing, family A member 5
PLCXD3 Phosphatidylinositol-specific phospholipase C, X domain containing 3 -1,8
MAPK8IP1 Mitogen-activated protein kinase 8 interacting protein 1 -1,7
ADD1 Adducin 1 (alpha) -1,7
COG1 Component of oligomeric golgi complex 1 -2,3
SFT2D3 SFT2 domain containing 3 -2,1
SULT2A1
Sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, 
member 1 -1,7
ATP8B3 ATPase, Class I, type 8B, member 3 -1,7
kinases/phosphatases
protein metabolism and transport
monocyte/macrophage-like differentiation factors
gene name description of up-regulated gene fold change
LOC653188 Similar to Beta-glucuronidase precursor 0,9
PSAT1 Phosphoserine aminotransferase 1 0,8
XYLT1 Xylosyltransferase I 0,8
AADAC Arylacetamide deacetylase (esterase) 0,7
KDELR2 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 0,7
ETV6 Ets variant gene 6 (TEL oncogene) 0,8
HIST2H2AA3 Histone 2, H2aa3 0,8
DNA-binding and proliferation
protein metabolism and transportBMC Cell Biology 2008, 9:12 http://www.biomedcentral.com/1471-2121/9/12
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Description of off-target effects during RNAi of VCP/p97 Figure 7
Description of off-target effects during RNAi of VCP/p97. Off-target effects reflect VCP/p97-siRNA-independent mod-
ulations of distinct genes. Only genes that were affected by both chosen VCP/p97-siRNAs were considered as down- or up-
regulated.
gene name description of off-target effects fold change
MICAL2 Microtubule associated monoxygenase, calponin and LIM domain containing 2 -2,6
NOX1 NADPH oxidase 1 -2,1
MMP13 Matrix metallopeptidase 13 (collagenase 3) -2,1
NFKBIL2 Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 2 -1,8
HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) -1,7
IL1R2 Interleukin 1 receptor, type II -1,7
ITGA2B Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) -1,6
TBC1D12 TBC1 domain family, member 12 -2,6
PLCXD1 Phosphatidylinositol-specific phospholipase C, X domain containing 1 -2,4
PTK7 PTK7 protein tyrosine kinase 7 -2,1
AKAP4 A kinase (PRKA) anchor protein 4 -2,0
PHKA2 Phosphorylase kinase, alpha 2 (liver) -1,9
GIT1 G protein-coupled receptor kinase interactor 1 -1,9
SHC4 SHC (Src homology 2 domain containing) family, member 4 -1,8
MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 -1,8
AAK1 AP2 associated kinase 1 -1,8
EGFR
Epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene 
homolog, avian) -1,8
GAP43 Growth associated protein 43 -1,7
NEK7 NIMA (never in mitosis gene a)-related kinase 7 -1,7
PTPRF Protein tyrosine phosphatase, receptor type, F -1,6
MAN2A2 Mannosidase, alpha, class 2A, member 2 -2,5
COPA Coatomer protein complex, subunit alpha -2,1
MRPL48 Mitochondrial ribosomal protein L48 -1,9
RAB17 RAB17, member RAS oncogene family -1,9
CASP1 Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) -1,8
CYP3A5 Cytochrome P450, family 3, subfamily A, polypeptide 5 -1,7
TAP2 Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) -1,7
POMT2 Protein-O-mannosyltransferase 2 -1,6
ANKRD12 Ankyrin repeat domain 12 1,3
GOLGB1 Golgi autoantigen, golgin subfamily b, macrogolgin (with transmembrane signal), 1 1,1
ANKRD10 Ankyrin repeat domain 10 0,9
PPIG Peptidylprolyl isomerase G (cyclophilin G) 0,8
GOLGA2 Golgi autoantigen, golgin subfamily a, 2 0,8
PMPCB Peptidase (mitochondrial processing) beta 0,8
NAALADL2 N-acetylated alpha-linked acidic dipeptidase-like 2 0,8
GSR Glutathione reductase 0,7
ATP6V1B1
ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 (Renal tubular acidosis 
with deafness) 0,7
PICALM Phosphatidylinositol binding clathrin assembly protein 0,7
CENPE Centromere protein E, 312kDa 0,8
MARK3 MAP/microtubule affinity-regulating kinase 3 0,8
MACF1 Microtubule-actin crosslinking factor 1 0,8
CHD9 Chromodomain helicase DNA binding protein 9 0,8
POLR2J2 DNA directed RNA polymerase II polypeptide J-related gene 0,8
CDK5RAP3 CDK5 regulatory subunit associated protein 3 0,8
RBBP6 Retinoblastoma binding protein 6 0,7
CEP350 Centrosomal protein 350kDa 0,7
MYCBP2 MYC binding protein 2 0,7
TNKS Tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 0,7
kinases/phosphatases
protein metabolism and transport
monocyte/macrophage-like differentiation factors
DNA-binding and proliferationBMC Cell Biology 2008, 9:12 http://www.biomedcentral.com/1471-2121/9/12
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apoptosis, ER stress and oxidative stress, respectively [40].
Together, the findings may be limited to possible off-tar-
get effects due to sequence-independent cellular response
to the siRNAs used.
The functions of VCP/p97 may contribute to the retrodif-
ferentiation process with certain levels of nuclear-associ-
ated VCP/p97 before retrodifferentiation. Indeed, other
work has demonstrated a simultaneous PARP-1-regulated
activation of the nuclear proteasome with maximal prote-
olytic activity at the time point of retrodifferentiation
[41,42]. Whereby inhibition of either PARP-1 or the pro-
teasome blocks the retrodifferentiation program [42],
these effects substantiate the importance of an intact pro-
teasomal regulation by factors such as VCP/p97 to restore
the undifferentiated U937 phenotype.
The requirement of VCP/p97 within the nucleus may also
involve other regulatory functions for the retrodifferentia-
tion program, which concludes the transition of a growth-
arrested differentiated population to autonomously pro-
liferating undifferentiated tumor cells. Such nuclear func-
tion was demonstrated for the interaction of VCP/p97
with DNA unwinding factor (DUF) in nuclei of Xenopus
egg extracts and suggested a role in DNA replication [43].
As a contribution to a tumor development, VCP/p97 has
been demonstrated to directly bind to BRCA1 as one of
the key regulatory genes in breast cancer pathogenesis
[13]. Since BRCA1 is involved in DNA damage repair, the
interaction with the ATP transporter VCP/p97 altered the
transcription-associated DNA repair [13]. Together, these
regulatory processes suggest a tightly controlled subcellu-
lar distribution of VCP/p97 according to the appropriate
cellular requirements. However, the signals for VCP/p97
to be directed to distinct subcellular compartments
remain unclear. In this context, it is interesting to note
that tyrosine phosphorylated VCP/p97 was exclusively
associated with the cytosol and the membrane fraction,
indicating a possible role for compartmentalization. This
is supported by previous findings which suggested a pos-
sible role for subcellular localization of VCP/p97 follow-
ing tyrosine phosphorylation [15,22]. Finally, these
effects are accompanied by the involvement of VCP/p97
in the TPA-mediated monocytic transition, affecting the
expression of differentiation-associated and cell cycle-reg-
ulatory genes. Moreover, genes involved in the ER-associ-
ated metabolic pathway were expressed at a significantly
reduced level, whereas expression of genes implicated in
post-translational modifications in the lysosomes and
microsomes was considerably increased, indicating a sup-
port and substitution of the protein biosynthesis and
quality control in the ER. This is further substantiated by
the enhanced expression of the KDEL ER protein retention
receptor [32].
Conclusion
Taken together, the present findings suggest that VCP/p97
expression is not altered during proliferation and cell
cycle progression. However, significantly increased pro-
tein and RNA levels appeared during G0/G1 cell cycle
arrest and an associated differentiation process. A certain
redistribution of VCP/p97 was observed in the membrane
and the nuclear fractions, carrying a tyrosine phosphor-
ylated form predominantly in the cytosolic and the mem-
branous compartments. The altered expression levels of
VCP/p97 during the TPA-induced differentiation of U937
cells as well as the changes of certain differentiation-asso-
ciated transcripts as a consequence of VCP/p97 RNAi sug-
gested that this AAA ATPase accompanies the
differentiation and retrodifferentiation process.
Methods
Cell culture
Human U937 myeloid leukemia cells were grown in
RPMI 1640 medium containing 10% fetal calf serum
(Biochrom, Hannover, Germany) supplemented with 100
units/ml penicillin, 100 µg/ml streptomycin and 2 mM L-
glutamine (PAA Laboratories GmbH, Cölbe, Germany).
The cells were treated with 10 nM TPA (Sigma, St. Louis,
MO, USA) for up to 72 h. The long term culture of adher-
ent TPA-differentiated U937 cells was performed in the
absence of TPA by changing the culture medium every 3
days until the cells entered the retrodifferentiation pro-
gram.
Centrifugal elutriation
The centrifugal elutriation was performed using the Beck-
mann J6-MC with the JE-5.0 rotor and the appropriate 5
ml-standard elutriation chamber (Beckman Coulter,
Krefeld, Germany). Approximately 109 U937 cells were
harvested, resuspended in PBS and applied to the stand-
ard chamber (1600 rpm at 24°C) using a digital flow con-
troller (Cole-Palmer Instruments Inc., Chicago, IL, USA).
Subsequent fractions of 100 ml aliquots of the elutriated
samples were collected upon progressive increase of the
pump speed. Elutriated cell fractions were examined for
cell cycle distribution.
Cell cycle distribution by FACS analysis
About 2 × 106 cells of the elutriated fractions were ana-
lyzed for distinct cell cycle phases as described previously
[11]. Briefly, the cells were harvested and fixed in 70% (v/
v) ice-cold ethanol and kept at 4°C for 24 h. Thereafter,
the fixed cells were stained with CyStain DNA 2 step kit
(Partec GmbH, Münster, Germany) and filtered through a
50 µm filter. These samples were then analyzed in a Gal-
axy flow cytometer (Dako, Hamburg, Germany) using
FloMax analysis software (Partec) and the MultiCycle cell
cycle software (Phoenix Flow Systems Inc., San Diego, CA,
USA).BMC Cell Biology 2008, 9:12 http://www.biomedcentral.com/1471-2121/9/12
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RNA isolation
About 5 × 106 cells were lysed in 2 ml TRIZOL Reagent
(Invitrogen, Karlsruhe, Germany) and incubated for 5
min at room temperature. After addition of 400 µl chloro-
form, the samples were mixed vigorously and then centri-
fuged for 15 min/12000 rpm at 4°C. An aliquot of 350 µl
of the aqueous upper phase was incubated for 5 min at
25°C and treated according to the RNeasy Mini Kit proto-
col (Qiagen, Hilden, Germany). To determine the RNA
concentration and integrity, the isolated RNA was ana-
lyzed in the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Böblingen, Germany) using the RNA 6000 Nano
LabChip Kit (Agilent Technologies) according to the man-
ufacturer's protocol.
RT-PCR
Reverse transcription was performed according to the
RevertAid First Stand cDNA Synthesis protocol with Ran-
dom Hexamer Primer (Fermentas GmbH, St. Leon Rot,
Germany) using 1000 ng of DNAse-treated RNA. An aliq-
uot of about 100 ng cDNA was amplified by quantitative
RT-PCR in the LightCycler 2.0 System using the Light
Cycler Software 3.5 (Roche Applied Science, Mannheim,
Germany) according to the LightCycler FastStart DNA
MasterPLUS Hybridisation Probes protocol (Roche). The
TATA-binding protein, TBP, was used as a reference. For
amplification, one cycle of 95°C for 15 min and then 40
cycles of 94°C for 15 s, 55°C for 25 s and 72°C for 25 s
were performed with VCP forward primer 5'-TTCCT-
GAAGTTTGGCATGACAC and reverse primer 5'-GCG-
GGCCTTGTCAAAGAT as well as TBP forward 5'-
TTCGGAGAGTTCTGGGATTGTA and reverse primer 5'-
TGGACTGTTCTTCACTCTTGGC, respectively (TIB MOL-
BIOL, Berlin, Germany). The following hybridisation
probes were used: VCP 5'-LC-Red640-CACCATGTGGTTT-
GGGGAGTCTGAG – PH and 5'-CTCCATCAAGGGTCCT-
GAGCTGC – FL and for TBP 5'-LC-Red640-
TGAGGATAAGAGAGCCACGAACCACG – PH and 5'-
CCAAGCCGGTTTGCTGCGGTAATC – FL. The RT-PCR
quantification was performed using the RelQuant soft-
ware (Roche).
Immunocytochemistry
For immunofluorescence, the differentiation/retrodiffer-
entiation process was performed on cover slips. The differ-
entiated cells became adherent to the glass surface
whereas U937 and retrodifferentiated cells were sedi-
mented on poly-L-lysine coated slides. The cells were fixed
with 4% (v/v) paraformaldehyde for 5 min at room tem-
perature. After neutralisation with 1 × TBS and permeabi-
lization with 0.1% (v/v) Triton X-100 in PBS, the slides
were incubated with an anti-VCP antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) in 3% BSA/PBS for
1 h at 37°C. After washing with PBS, the slides were incu-
bated for 1 h at 37°C with a FITC-conjugated secondary
antibody (Dianova, Hamburg, Germany) diluted 1:1000
in 3% BSA/PBS. Following an additional washing step,
further incubation was performed with the DNA-interca-
lating dye Hoechst33258 (Invitrogen) for detection of the
nuclei. After two final washing steps with PBS, the slides
were mounted using ProLong Antifade (Invitrogen).
Additionally, the specificity of the VCP antibody was
tested in a neutralization reaction. Therefore, the VCP
antibody was preabsorbed with the appropriate specific
VCP peptide (Santa Cruz Biotechnology) according to the
manufacturer's protocol. The prepared slides were incu-
bated as described above for 1 h at 37°C using this anti-
body-peptide-mixture instead of the primary antibody.
Epifluorescence microscopy was performed with a Zeiss
Axiovert 200 M microscope using the Zeiss Axiovision
software (Carl Zeiss, Göttingen, Germany).
Separation of proteins from subcellular compartments
Separation of the different cellular compartment proteins
was performed using the Qproteome cell compartment kit
(Qiagen, Hilden, Germany). About 1 × 107 cells were har-
vested and lyzed according to the Qiagen protocol. All
buffers were supplemented with protease inhibitors
(according to the Qiagen protocol) and 1 mM NaVO3 as
phosphatase inhibitor. The obtained proteins of the sub-
cellular compartments were concentrated and desalted by
acetone precipitation. Thereafter, the pellets were resu-
pended in the appropriate buffer depending on further
analysis.
Immunoprecipitation
The immunoprecipitation was performed by the µMACS
Protein G-MicroBeads method (protocol according to the
manufacturer's recommendation; Miltenyi Biotech, Ber-
gisch Gladbach, Germany). Briefly, the acetone-precipi-
tated proteins were resuspended in 1 ml lysis buffer pH
7.5 containing 20 mM Tris, 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 2,5 mM NaPPi, 1 mM β-glycerolphosphate,
1 mM NaVO3, 1 µg/ml leupeptin, 1% (v/v) Triton-X-100,
0.5% (v/v) Nonidet-NP40 and 1 mM PMSF. For preab-
sorption of non-specific binding proteins, 50 µl µMACS
Protein G-MicroBeads (Miltenyi Biotech) were added to
the protein homogenate of the appropriate subcellular
compartment and incubated for 30 min at 4°C. Thereaf-
ter, the suspension was applied onto the prepared µ-Col-
umn (Miltenyi Biotech) within the magnetic field of the
µMACS Separator (Miltenyi Biotech). The flowthrough
was collected in a new reaction tube and reused for subse-
quent antibody-incubation. For the immunoprecipita-
tion, 1 µg of anti-phosphotyrosine antibody (clone 4G10,
Upstate Biotechnology, Lake Placid, NY, USA) or 1 µg of
anti-VCP antibody (Novus Biologicals, Littleton, CO,
USA), respectively, and 50 µl  µMACS Protein G-BMC Cell Biology 2008, 9:12 http://www.biomedcentral.com/1471-2121/9/12
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MicroBeads were added to the protein homogenates. After
incubation for 30 min at 4°C, the suspension was applied
onto new µ-Columns and several washing steps with lysis
buffer were performed according to the manufacturer's
protocol (Miltenyi). Finally, a low salt buffer, containing
20 mM Tris-HCl pH 7.5, was added and elution was per-
formed using an adequate buffer, e.g. 50 µl 1× SDS gel
loading buffer (95°C) for subsequent SDS-PAGE.
Two-dimensional (2D) polyacrylamide gel electrophoresis 
(SDS-PAGE)
The proteins of the different subcellular compartments
were separated by isoelectric focusing (IEF) followed by
SDS-PAGE in the second dimension, respectively. Thus,
the proteins were incubated in reswelling buffer (8 M
urea, 1% CHAPS (v/v), 0.5% pharmalytes 3–10 (v/v),
0,002% bromphenol blue (w/v), 0,4% DTT (w/v); accord-
ing to the Amersham protocol) on an 18 cm IPG-Immo-
biline Dry Strip (pH 3–10; NL) (Amersham Biosciences
GmbH, Freiburg, Germany) and separated for 18 h at 150
V in the first dimension using the IPGphor isoelectric
focusing system (Amersham). Thereafter, the IPG strips
were incubated in two subsequent equilibration buffers
for 15 min, respectively (according to the Amersham pro-
tocol), and polymerised on a 10% SDS-PAGE separation
gel using 0.5% (w/v) low melting point agarose. Electro-
phoresis was standardized using appropriate molecular-
weight markers (Amersham).
Immunoblot analysis
SDS-PAGE was performed in a 10% and 7.5% separation
gel, respectively, and was standardized using prestained
low-molecular-weight markers (Bio-Rad, Munich, Ger-
many). Following protein transfer to nitrocellulose mem-
brane filters (Amersham Bioscience GmbH, Freiburg,
Germany), the blots were incubated with a monoclonal
antibody against VCP/p97 (Progen Biotechnik GmbH,
Heidelberg, Germany) and a monoclonal anti-phospho-
tyrosine antibody (clone 4G10, Upstate Biotechnology,
Lake Placid, USA). Appropriate antibodies against
selected subcellular compartment standard proteins such
as anti-GAPDH (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) for the cytosol, anti-clathrin (Progen) for the
membrane fraction and anti-nucleoporin62 (BD
Pharmingen, San Diego, CA, USA) for the nuclear com-
partment were used to ensure an appropriate subcellular
separation. Following incubation with a peroxidase-con-
jugated secondary antibody (Amersham), the blots were
developed using an electrochemiluminescence (ECL)
detection kit (Perkin Elmer, Boston, MA, USA).
siRNA-transfection
Transfection of the cells was performed according to the
manufaturer's protocol (amaxa GmbH, Cologne, Ger-
many). Briefly, 1 × 106 U937 cells were harvested and
resuspended in 100 µl Nucleofector Solution V (amaxa).
The cell suspension was mixed with 1 µg siRNA, placed in
a sterile electroporation cuvette and subjected to program
T20 using the Nucleofector II (amaxa). For transfection,
the following siRNAs were used: GW VAL siRNA
Hs_VCP_6 and GW VAL siRNA Hs_VCP_7 to target VCP/
p97, AllStars Negative Control siRNA as a negative con-
trol, and Negative Control siRNA AF488 as a FITC-conju-
gated negative control (all from Qiagen, Hilden,
Germany), respectively. After transfection, the cells were
immediately transferred into pre-warmed culture
medium, supplemented with 10% FCS. To evaluate the
transfection efficiency, U937 controls and cells trans-
fected with Negative Control siRNA AF488 were harvested
after 5 h, washed twice with PBS and subjected to the Gal-
axy flow cytometer (Dako) using FloMax analysis software
(Partec). For VCP/p97 Western blot analysis, the trans-
fected cells were harvested 72 h post transfection and
treatment with 10 nM TPA was performed for 24 h.
cDNA microarray analysis
For cDNA microarray experiments U937 cells were trans-
fected either with negative control siRNA, the two VCP/
p97 siRNAs together or each VCP/p97 siRNA separately,
respectively. The differentiation process of these four pop-
ulations was initiated 48 h after transfection by treating
the cells with 10 nM TPA for additional 24 h. Control cul-
tures were maintained in medium for 72 h after transfec-
tion. Following RNA extraction, 1 µg of total RNA was
linearly amplified using the MessageAmp aRNA Kit
(Ambion, Huntington, UK). Quantification and valida-
tion for integrity was performed on an Agilent 2100 Bio-
analyzer using the RNA 6000 Nano LabChip Kit according
to the manufacturer's protocol (Agilent Technologies,
Böblingen, Germany). Three µg of amplified RNA from
the different VCP/p97 siRNA transfected cells of both, the
untreated and TPA-treated population, was labelled with
Cy5-dUTP, whereas the amplified RNA from negative
control siRNA transfected cells was similarly labelled with
Cy3-dUTP according to the provided protocol (Amer-
sham Biosciences), respectively. To evaluate off-target
effects, we performed microarray analysis of pooled tripli-
cates of transfected cells with each of the VCP/p97 siRNAs
separately, and then compared these results to the micro-
array data of both VCP/p97 siRNAs together. The fluores-
cence-labelled RNA probes were comparatively
hybridised on a spotted cDNA microarray (Stanford Func-
tional Genomics Facility, Stanford, CA, USA) following
the posted protocol [44]. The fluorescence intensities of
Cy5 and Cy3 were measured on a GenePix 4000 scanner
(Axon Instruments, Foster City, CA, USA) and analyzed
using GenePix Pro 4.1 software (Axon Instruments). Areas
of the microarray or spots exhibiting obvious damages
due to technical failures were excluded from subsequent
analysis. Single spots were only considered as well-meas-BMC Cell Biology 2008, 9:12 http://www.biomedcentral.com/1471-2121/9/12
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ured and included in the further investigation, when the
mean fluorescent intensity of Cy5 and Cy3 was ≥ 3-fold
above the local background and the regression correlation
was ≥ 0.8. Genes were classified as upregulated, when the
corresponding spot met these quality criteria and a log
(base 2) ratio of Cy5 relative to Cy3 revealed a value of ≥
0.7. Thus, U937 control transfectants were compared to
VCP/p97 transfectants and simultaneously TPA-treated
control-transfectants were compared to the appropriate
TPA-treated VCP/p97 transfectants to exclude those genes
affected by the transfection itself. Thereafter, the regulated
genes of untreated and TPA-treated populations were
compared in order to exclusively evaluate transcripts
affected by VCP/p97 during the differentiation process.
Finally, these gene expressions were cleared by the off-tar-
get effects. All cDNA microarray expression data, includ-
ing the off-target effects, are stored online with the
accession number GSE9821 at the GEO website [45].
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